ClinicalTrials.gg

Program

serabelisib

Also written as “TAK-117”, “Serabelisib” and “MLN1117”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Neoplasms · Clear-cell metastatic renal cell carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 2, since Mar 15, 201511 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda70 open or runningphase 2since Mar 15, 2015Aug 11, 2011none ahead
Faeth Therapeutics32 open or runningphase 2since Jun 11, 2024Jan 31, 2022Sep 2028phase 2 · NCT06463028
Petra Pharma10 open or runningphase 2since Aug 26, 2019Aug 26, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2011First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesNew to TakedaTakeda · NCT01449370 · 125 enrolled · United States, Spain, United Kingdom
  2. Jul 10, 2013Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01899053 · 101 enrolled · United States, Spain, United Kingdom
  3. Mar 15, 2015Phase 2 study in Carcinoma, Non-Small-Cell LungTakeda · NCT02393209 · 14 enrolled · United States, Canada, Netherlands
  4. Sep 2, 2015Phase 1 study in Advanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaTakeda · NCT02551055 · 32 enrolled · United States, Spain
  5. Dec 4, 2015Phase 1 study in NeoplasmsTakeda · NCT02625259 · 54 enrolled
  6. Mar 25, 20162 phase 2 studiesTakeda · NCT02724020, NCT02725268
  7. Aug 26, 2019Petra Pharma's first study: phase 2 study in Breast NeoplasmsNew to Petra PharmaPetra Pharma · NCT04073680 · 60 enrolled
  8. Jan 31, 2022Faeth Therapeutics's first study: phase 1 study in Advanced Solid TumorNew to Faeth TherapeuticsFaeth Therapeutics · NCT05300048 · 34 enrolled · United States
  9. Jun 11, 2024Phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028 · 40 planned · United States
  10. Apr 17, 2026Phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733 · 32 planned · United States

Ahead

  1. Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028
  2. May 2029Primary completion: phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07558733Breast Neoplasms · United States2RecruitingFaeth TherapeuticsMay 202932
NCT06463028Endometrial Neoplasms · United States2RecruitingFaeth TherapeuticsSep 202840
NCT05300048Advanced Solid Tumor · United States1TerminatedFaeth TherapeuticsApr 30, 202534
NCT04073680Breast Neoplasms2UNKNOWNPetra PharmaJul 15, 202160
NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more2CompletedTakedaJul 2, 2019241
NCT02724020Clear-cell metastatic renal cell carcinoma · United States, Canada, Czechia and more2CompletedTakedaFeb 3, 202096
NCT02625259Neoplasms1CompletedTakedaMay 16, 201654
NCT02551055Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma · United States, Spain1TerminatedTakedaFeb 17, 201732
NCT02393209Carcinoma, Non-Small-Cell Lung · United States, Canada, Netherlands2TerminatedTakedaJan 12, 201714
NCT01899053Advanced Nonhematologic Malignancies · United States, Spain, United Kingdom1CompletedTakedaJan 31, 2017101
NCT01449370Hereditary Sensory and Autonomic Neuropathies · United States, Spain, United Kingdom1CompletedTakedaJul 2015125

How it is read

Names in the registry

  • “TAK-117”, 5 entries
  • “Serabelisib”, 4 entries
  • “MLN1117”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.